drugset / Trial / NCT00365339

Drug Interaction Study With Famotidine, Atazanavir, and Atazanavir/Ritonavir/Tenofovir

NCT00365339

Phase 1 Completed 40 enrolled Bristol-Myers Squibb
RandomizedParallel-groupOpen-label

Summary

The purpose of this clinical research study is to assess the pharmacokinetics of atazanavir, identifying one or more dosing regimens of atazanavir/ritonavir/tenofovir when dosed with famotidine results in atazanavir exposures similar to those when atazanavir/ritonavir/tenofovir 300/100/300 mg is dosed without famotidine in healthy subjects.

Timeline

Start
2006-04
Primary completion
2006-06
Completion
2006-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Atazanavir Other / unclassified 300 mg Oral
Subject Famotidine Other / unclassified 20 mg Oral
Subject Famotidine Other / unclassified 40 mg Oral
Comparator Ritonavir Other / unclassified 100 mg Oral
Comparator Tenofovir Small molecule 300 mg Oral